Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Data from Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> Trial
Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey Matous, D. Blair Macdonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango‐Hisijara, Meletios A Dimopoulos (2024). Data from Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> Trial. , DOI: https://doi.org/10.1158/1078-0432.c.7524179.
Preprint24 days agoSupplementary Data from Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> Trial
Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey Matous, D. Blair Macdonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango‐Hisijara, Meletios A Dimopoulos (2024). Supplementary Data from Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> Trial. , DOI: https://doi.org/10.1158/1078-0432.27609983.
Preprint24 days agoLong-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
Judith Trotman, Katherine Rankin, Ibrahim Tohidi‐Esfahani, Alessandra Tedeschi, Constantine S. Tam, Christian Buske, Roger G. Owen, Véronique Leblond, Meletios A Dimopoulos, Philip M. Smallwood, Heather Allewelt, Wai‐Yee Chan, Radha Prathikanti, Jingjing Schneider, Remus Vezan, Stephen Opat (2024). Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM). , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-200334.
Article24 days agoPeripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
Benjamin Heyman, Stephen Opat, Björn E. Wahlin, Meletios A Dimopoulos, Jorge J. Castillo, Alessandra Tedeschi, Constantine S. Tam, Christian Buske, Roger G. Owen, Véronique Leblond, Judith Trotman, Gisoo Barnes, Wai‐Yee Chan, Jingjing Schneider, Heather Allewelt, Aileen Cleary Cohen, Jeffrey Matous (2024). Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. , 9(4), DOI: https://doi.org/10.1182/bloodadvances.2024014115.
Article24 days agoHealth-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial
Alessandra Tedeschi, Constantine S. Tam, Roger G. Owen, Christian Buske, Véronique Leblond, Meletios A Dimopoulos, Ramón García‐Sánz, Jorge J. Castillo, Judith Trotman, Steven P. Treon, Keri Yang, Boxiong Tang, Heather Allewelt, Sheel Patel, Wai‐Yee Chan, Aileen Cleary Cohen, Shengnan Chen, Gisoo Barnes (2024). Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial. , 20(25), DOI: https://doi.org/10.1080/14796694.2024.2355079.
Article24 days ago